PharmaNet/i3 Appoints Neuroscience GM

Robert Lasser, M.D., has been appointed vice president and general manager of Neuroscience at PharmaNet/i3. Dr. Lasser is responsible for overseeing the management of all clinical projects handled by the Neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, NJ.
 
Dr. Lasser has more than 18 years of experience in medical practice and the pharmaceutical industry. He joins the company from Shire Pharmaceuticals, where he served as general manager for VYVANSE New Uses in multiple central nervous system (CNS) indications. Dr. Lasser previously served as Shire’s senior director in Clinical Development-Medical Affairs, overseeing clinical, medical and scientific input to the lifecycle for CNS therapeutics. He also held positions of increasing seniority at leading pharmaceutical companies, where he directed global CNS medical strategy and clinical studies.
 
“Having led successful clinical development programs, Robert brings a wealth of neuroscience expertise and clinical leadership skills to PharmaNet/i3,” said PharmaNet/i3’s Alison O’Neill, Senior Vice President, Global Therapeutics and Clinical Operations, North America. “The addition of Robert to the helm of our experienced neuroscience team enhances our ability to exceed our clients’ expectations for the specialized solutions needed to successfully conduct their neuroscience clinical studies.”